Logo
x

Search

Subscribe Now

Daiichi Sankyo

Daiichi Sankyo and AstraZeneca Report the EC’s Approval of Enhertu for HER2 Low/Ultralow Metastatic Breast Cancer (MBC)

Daiichi Sankyo and AstraZeneca Report the EC’s Approval of Enhertu for HER2 Low/Ultralow Metastatic Breast Cancer (MBC)

  • April 4, 2025
Daiichi Sankyo Reports the First Patient Dosing in P-III (DESTINY-Gastric05) Trial of Enhertu Regimen to Treat G/GEJ Cancer

Daiichi Sankyo Reports the First Patient Dosing in P-III (DESTINY-Gastric05) Trial of Enhertu Regimen to Treat G/GEJ Cancer

  • April 2, 2025
Daiichi Sankyo Reports Interim Data of P-III (DESTINY-Gastric04) Study Evaluating Enhertu in HER2+ Metastatic Gastric Cancer Patients

Daiichi Sankyo Reports Interim Data of P-III (DESTINY-Gastric04) Study Evaluating Enhertu in HER2+ Metastatic Gastric Cancer Patie...

  • March 4, 2025
Daiichi Sankyo and AstraZeneca Dose the First Patient with Adjuvant Datroway in P-III (TROPION-Lung12) Trial for Adenocarcinoma NSCLC

Daiichi Sankyo and AstraZeneca Dose the First Patient with Adjuvant Datroway in P-III (TROPION-Lung12) Trial for Adenocarcinoma NS...

  • January 31, 2025
Daiichi Sankyo and AstraZeneca Report the US FDA’s Approval of Enhertu for HER2 Low/Ultralow Metastatic Breast Cancer (MBC), Progressed on Endocrine Therapies

Daiichi Sankyo and AstraZeneca Report the US FDA’s Approval of Enhertu for HER2 Low/Ultralow Metastatic Breast Cancer (MBC), Progr...

  • January 28, 2025
Daiichi Sankyo and AstraZeneca Receives the US FDA Approval for Datroway (Datopotamab Deruxtecan-dlnk) to Treat HR+/HER2- Metastatic Breast Cancer

Daiichi Sankyo and AstraZeneca Receives the US FDA Approval for Datroway (Datopotamab Deruxtecan-dlnk) to Treat HR+/HER2- Metastat...

  • January 20, 2025
Daiichi Sankyo and AstraZeneca Report the US FDA’s Approval of Enhertu for HER2 Low/Ultralow Metastatic Breast Cancer (MBC), Progressed on Endocrine Therapies

    Daiichi Sankyo and AstraZeneca Report the US FDA’s Approval of Enhertu for HER2 Low/Ultralow Metastatic Breast Cancer (MBC), Progr...

    • January 28, 2025
    Daiichi Sankyo and AstraZeneca Receives the US FDA Approval for Datroway (Datopotamab Deruxtecan-dlnk) to Treat HR+/HER2- Metastatic Breast Cancer

      Daiichi Sankyo and AstraZeneca Receives the US FDA Approval for Datroway (Datopotamab Deruxtecan-dlnk) to Treat HR+/HER2- Metastat...

      • January 20, 2025
      AstraZeneca and Daiichi Sankyo Report the US FDA’s BLA Acceptance of Datopotamab Deruxtecan with Priority Review for EGFR-mutated NSCLC

        AstraZeneca and Daiichi Sankyo Report the US FDA’s BLA Acceptance of Datopotamab Deruxtecan with Priority Review for EGFR-mutated...

        • January 15, 2025
        Daiichi Sankyo’s Datroway Receives the MHLW’s Approval for Unresectable or Recurrent HR+/HER2- Breast Cancer

          Daiichi Sankyo’s Datroway Receives the MHLW’s Approval for Unresectable or Recurrent HR+/HER2- Breast Cancer

          • December 27, 2024
          Daiichi Sankyo Begins the P-III (QuANTUM-Wild) Study of Vanflyta (Quizartinib) to Treat FLT3-ITD Negative Acute Myeloid Leukemia (AML)

            Daiichi Sankyo Begins the P-III (QuANTUM-Wild) Study of Vanflyta (Quizartinib) to Treat FLT3-ITD Negative Acute Myeloid Leukemia (...

            • December 11, 2024
            Daiichi Sankyo Reports Pooled Analysis from TROPION-Lung05 & TROPION-Lung01 Trials of Datopotamab Deruxtecan (Dato-DXd) for NSCLC

              Daiichi Sankyo Reports Pooled Analysis from TROPION-Lung05 & TROPION-Lung01 Trials of Datopotamab Deruxtecan (Dato-DXd) for NSCLC

              • December 6, 2024
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.